BioCentury | Jul 25, 2020
Product Development

NIH, HHS fast-tracking point-of-care, pooled tech as way out of testing crunch

The U.S. government is taking non-conventional paths to point-of-care and pooled technologies in its push to bulk up and speed up the country’s strained COVID-19 testing capacity. In HHS’s case, the department is scrambling to...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

Researchers are finding new ways to monitor the immune system in hematologic diseases that could have implications for optimizing immuno-oncology therapies, according to BioCentury’s analysis of emerging targets at ASH 2019. In abstracts released ahead...
BioCentury | Nov 9, 2019
Financial News

Nov. 8 Financial Quick Takes: First day of trading for BrightGene, Tot; plus argenx, Agios and AiCure

BrightGene shines in STAR debut BrightGene Bio-Medical Technology Co. Ltd. (Shanghai:688166) gained RMB17.90 (141%) to RMB30.61 in its first day of trading on Shanghai’s STAR board. The company raised RMB521.1 million ($74.1 million) in an...
BioCentury | Nov 7, 2019
Financial News

More weakness among IPOs as Galera, Centogene limp into marketplace

Cancer company Galera became the latest biotech whose NASDAQ IPO fell short of expectations, while shares of diagnostics company Centogene dipped after pricing its offering at the low end of its proposed range. A third...
BioCentury | Sep 4, 2019

Repare readies for clinic with Cowen-led $82M B round

To bring Repare’s pipeline to the clinic and expand the use of its CRISPR-based screening platform, Cowen Healthcare Investments led the synthetic lethality company’s untranched $82.5 million series B round. Cowen’s Kevin Raidy said that...
BioCentury | Aug 8, 2019
Distillery Techniques

Mice with wild microbiomes predict clinical results

TECHNIQUES CATEGORY: Disease models TECHNOLOGY: Animal models NIH's National Institute of Diabetes and Digestive and Kidney Diseases created a laboratory mouse model with a wild microbiome that could yield better predictions of clinical results than...
BioCentury | Jul 31, 2019
Financial News

Alizé seeks to build out company with largest European A round this year

French biotech Alizé Pharma 3 is taking a more ambitious approach than its predecessors, and now has a €67 million ($74.5 million) series A round to fund two endocrine programs through Phase II testing and...
BioCentury | Jun 7, 2019
Clinical News

June 7 Clinical Quick Takes: Takeda discontinues Ninlaro for amyloidosis; plus La Jolla, Innovent and Atara

Takeda discontinues amyloidosis trial Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) discontinued the Phase III TOURMALINE-AL1 trial to treat relapsed or refractory systemic amyloid light-chain (AL) amyloidosis after Ninlaro ixazomib plus dexamethasone missed the first of...
BioCentury | Apr 6, 2019

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
BioCentury | Mar 16, 2019
Politics, Policy & Law

Spreading the costs and pain in Part D

The Trump administration’s proposed changes to Medicare Part D would shift costs from the federal government to patients, manufacturers and insurers, all of which are sure to lobby against it and derail it in Congress....
Items per page:
1 - 10 of 72